Mr. Eric Ah-Yon

Mr. Eric Ah-Yon is the president of a privately held investment firm, Mickeric Enterprises Ltd., that holds a portfolio of privately held assets and publicly listed companies across various industry sectors. He has done extensive due diligence on numerous companies and is knowledgeable in business operations, management, and corporate financing. Mr. Ah-Yon is also experienced in the real estate development, building construction and property management. In addition, he is the managing director of Vencompass Group Enterprises Ltd., a firm investing primarily in seed and early stage companies requiring private equity financing and Cellbox Solutions Inc., an I.T. based company. Mr. Ah-Yon holds a Bachelor of Business Administration in Finance and Management from Simon Fraser University and a Diploma of Technology in Building Engineering Technology Economics / Construction Operations from the British Columbia Institute of Technology.

Dr. William Campbell, Ph.D., Chairman of the Board

Dr. William Campbell is currently the president of Biomime Solutions, a British Columbia incorporated biotechnology consulting firm, and the CEO of PepMetric Technologies a peptide-based drug design company. His main areas of scientific activity in recent years have been in the development of peptide arrays and software capable of identifying peptides that can interact with specifically with proteins such as HIV 1 reverse transcriptase, endothelin and its receptor, and C5A and its receptor. Dr. Campbell is a discoverer of the carboxypeptidase, CPR , which is an important enzyme with dual functions as a regulator of fibrinolysis and inflammation. Over the last 30 years, Dr. Campbell has divided his time between Japan and Canada, most recently as assistant professor at Nagoya City University in the Department of Molecular Biology and then at the Choju Medical Institute in Toyohashi. His previous early employment includes work on the determination of air borne contaminants for the Department of Health and Welfare Canada, and the development of heterocyclic amines of biological interest for Pharma Research (Boeringer) in Montreal. Dr. Campbell completed his B.Sc. in Chemistry at Concordia University (1962) and obtained his PhD in Microbiology and immunology from the University of Montreal (1971). In addition to his notable achievements as a scientist and entrepreneur, Dr. Campbell is also an accomplished fine artist. He studied painting at Concordia University, McGill University and the Montreal Museum of Fine Art School. He also holds a diploma in photography from the Dawson Institute of Photography in Montreal. He has held numerous exhibitions of his works in Canada and Japan. Some of his most recent works adorn the Science and Technology pages of this website.

Dr. Steven Pelech, Ph.D.

Dr. Pelech is the principal founder of Kinexus Bioinformatics Corporation. He contributes leadership, vision and strategic planning to Kinexus with over twenty-five years experience in the areas of science, business and administration. He was the principal founder of Kinetek Pharmaceuticals, Inc. and served as its President and C.E.O. for six years and was one of the founding scientists of the Biomedical Research Center. Prior to his academic and industrial experience, he spent five years in post-doctoral training with Sir Philip Cohen at the University of Dundee in Scotland and Nobel laureate Dr. Edwin Krebs at the University of Washington in Seattle. He is concurrently a full professor in the Department of Medicine at the University of British Columbia (UBC), where he has been on faculty since 1988. Dr. Pelech received his B.Sc. (1979; Honours) and Ph.D. (1982) degrees in Biochemistry from UBC.

Dr. T. Nathan Yoganathan, Ph.D.

Dr. T. Nathan Yoganathan is the President and Chief Executive Officer of Kalgene Pharmaceuticals Inc., a Canadian company focused on developing and commercializing novel cancer therapies. Dr. Yoganathan was the founder, and former Chairman, President and Chief Scientific Officer of Med BioGene Inc, a Canadian diagnostics company listed on TSX Venture Exchange. Dr. Yoganathan has over 21 years of experience in scientific research in cell signalling and gene expression technology. He is the recipient of numerous awards including ones from the Natural Sciences and Engineering Research Council of Canada and the Thyroid Foundation of Canada. He also serves as a mentor for the student biotechnology network (SBN) of British Columbia. Dr. Yoganathan was a faculty member of the Department of Medicine at the University of Toronto and was affiliated with the Mt. Sinai Samuel Lunenfeld Research Institute. He holds a B.Sc. (Honours) from the University of North London, a M.Sc. from the University of Sussex and a Ph.D. from the University of Oslo.